Positive outlook
- Premiumization well on track despite COVID headwinds, with ASP set to grow by c.5% in FY22/FY23, powering margin improvements
- Continuing expansion in China along with decent recovery in South Korea to boost revenue growth
- Maintain BUY with TP of HK$32.77